Slides
Page 1
Q4 FY26 Earnings Call August 6 , 2026 Resmed
Page 2
Data Vis Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc. ("Resmed"), its subsidiaries, and its legal entities for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include non-GAAP Gross Profit, non-GAAP Gross Margin, non-GAAP Income from Operations, non-GAAP Net Income, and non-GAAP Diluted Earnings per Share, should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of the non-GAAP financial measures to the most comparable GAAP measures, please refer to the earnings release associated with the relevant reporting period, which can be found on the investor relations section of our corporate website ( investor.Resmed.com). In addition to historical information, this presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Resmed’s current expectations of future revenue or earnings, new product development, ne w product launches, new markets for its products, integration of acquisitions, leveraging of strategic investments, litigation, and outlook. The words “believe,” “e xpect,” “intend,” “anticipate,” “will continue,” “will,” “estimate,” “plan,” “future” and other similar expressions, and negative statements of such expressions, generally identify f orward-looking statements, including, in particular, statements regarding expectations of future revenue or earnings, expenses, new product development, new product launches, new markets for our products, the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, outlook, and the expected im pact of macroeconomic conditions on our business. We have not included a reconciliation for forward-looking non-GAAP financial measures where we are unable to provide a meaningful or accurate calculation or estimation of reconciling items, and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the occurrence and the financial impact of various items that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Forward-looking non-GAAP financial measures provided without the most directly comparable GAAP financial measures may vary materially from the corresponding GAAP financial measures. Resmed’s expectations, beliefs, and forecasts are expressed in good faith and are believed to have a reasonable basis, but ac tual results could differ materially from those stated or implied by these forward-looking statements due to risks, uncertainties, and other factors. Resm ed assumes no obligation to update the forward- looking information in this presentation, whether as a result of new information, future events, or otherwise. For further discussion of the various factors that could impact actual events o r results, please review the “Risk Factors” identified in Resmed’s quarterly and annual reports filed with the SEC. All forward-looking statements included in this presentation should be considered in the context of these risks. Investors and prospective investors are cau tioned not to unduly rely on our forward-looking statements. Presentation of financial information & forward-looking statements 2© 2026 Resmed.
Page 3
Data Vis Strong results in Q4 closed out another great fiscal year © 2026 Resmed. Q4 FY26 FY26 Total Revenue $1.5B 9% HL YoY growth 8% CC YoY growth $5.7B 10% HL YoY growth 8% CC YoY growth Non-GAAP EPS $2.95 16% YoY growth $11.17 17% YoY growth Free Cash Flow $404M $287M Returned to Shareholders1 $1.6B $1B Returned to Shareholders1 3Note: Data as of June 30, 2026. Resmed’s fiscal year end is June 30th. Note: See reconciliation to GAAP in Appendix. Note: CC = constant currency. HL = headline. YoY = year-over-year. 1 Includes share buybacks and dividends paid.
Page 4
Data Vis © 2026 Resmed. 4 Operational and Innovation Excellence Active Portfolio Management Invest in Business and Return Capital to Shareholders Key areas of focus that will continue contributing to Resmed’s growth and transformation 1 2 3 Resmed key areas of focus
Page 5
Data Vis © 2026 Resmed. 5 + Improvement of sleep pathway through key partnerships Resmed + ŌURA Early KPIs: ~13K Resmed.com visits 75% of assessment takers undiagnosed I. Operational & Innovation Excellence II. Active Portfolio Management III. Business Investment & Return of Capital partnered to expand access to sleep health education and care: Oura member experiences a higher number of nighttime breathing disturbances 1 Member is referred to Resmed’s resources, including a sleep assessment 2 Member has the option to connect with independent provider, virtually or in person 3 Potential Resmed patient 4
Page 6
Data Vis Source: IQVIA LRX data and Diagnostic claims, July 2021 – March 2026. 1 Total patients with an OSA diagnosis claim from July 2021 – March 2026; those who were diagnosed with OSA prior to July 2021 are not included in this analysis. 2 GLP-1 initiation is defined by presence of GLP-1 claim at any point from July 2021 – March 2026 (n=2,593k patients); initiation does not demonstrate GLP-1 treatment adherence, so patients may not be actively taking GLP-1s today. 3 Values show absolute percentage difference in presence of any PAP-related claim from July 2021 – March 2026 comparing OSA patients who used GLP-1s versus OSA patients with no GLP-1 use. 4 Values show absolute percentage difference in presence of any PAP-related claim at each timepoint post PAP setup from July 2021– March 2026 comparing OSA patients who used GLP-1s versus OSA patients with no GLP-1 use. 5 Majority of patients in the analysis population were prescribed newer GLP-1 drugs: semaglutide or tirzepatide. Large real-world data analysis: n = 2,593,000 patients with GLP-1 initiation, sleep apnea diagnosis, and Rx for PAP therapy5 Patients with an OSA diagnosis and prescribed a GLP-1 drug are more likely to initiate PAP therapy and have higher PAP resupply rates GLP-1 initiated1,2 vs. non-GLP-1 initiated OSA patients1 PAP resupply rates4 1-year post-setup +340 bps +1070 bps GLP-1Non-GLP-1 Likely to initiate PAP therapy3 PAP resupply rates4 3-year post-setup +600 bps Real-world data analysis now shows >2.5M patients on GLP-1s both initiate CPAP more and stay on therapy 6© 2026 Resmed. GLP-1Non-GLP-1 GLP-1Non-GLP-1 I. Operational & Innovation Excellence II. Active Portfolio Management III. Business Investment & Return of Capital
Page 7
Data Vis PAP Leads GLP-1s in OSA treatment initiation 7© 2026 Resmed. GLP Gradual increase after OSA diagnosis PAP Increased rapidly immediately after diagnosis Source: Sterling KL, et al. PAP therapy and GLP-1 use before and after medication label expansion to treat OSA. Presented at SLEEP conference, June 2026. 1 Includes data from CY2025, N=~179K. ✓ Among newly diagnosed OSA patients, PAP was initiated earlier than GLP-1s ✓ At 90 days after a positive OSA diagnosis, >40% of patients had started on PAP vs. <3% on a GLP-1 ✓ The proportion of patients with PAP increased faster after diagnosis than GLP-1 initiations Time from sleep test to receipt of therapy after label expansion, by therapy1 I. Operational & Innovation Excellence II. Active Portfolio Management III. Business Investment & Return of Capital
Page 8
Data Vis Female patients represent a larger share of new patient starts (+4 pts vs. 2019) Since 2015, patients under 44 have become a larger share of new starts These trends inform Resmed’s promotional efforts, our product designs, and our educational content We are seeing demographic shifts in our OSA patient population toward more women and younger patients 8© 2026 Resmed. Source: IQVIA data. I. Operational & Innovation Excellence II. Active Portfolio Management III. Business Investment & Return of Capital
Page 9
Data Vis I. Operational & Innovation Excellence II. Active Portfolio Management III. Business Investment & Return of Capital ✓ >95,000 CME courses completed ✓By >55,000 clinicians ✓With ~77% Saying they intend to change their clinical practices with regards to OSA Clinicians are highly engaged with Resmed education programs focused on sleep 9 Up ~15K Up ~10K Note: Data as of June 30, 2026. Note: Data compares Q4 FY26 values vs. Q3 FY26 values. © 2026 Resmed.
Page 10
Data Vis I. Operational & Innovation Excellence II. Active Portfolio Management III. Business Investment & Return of Capital AirTouchTM N30i • Fabric-wrapped nasal mask designed to deliver exceptional comfort, more natural sleep experience AirSenseTM 11 and AirCurveTM 11 ST/ST-A • AirSenseTM 11 most recently launched in China and Taiwan • AirCurveTM 11 ST/ST-A launched in the U.S. Resmed is an innovation machine 10© 2026 Resmed. AirFitTM F40 • Minimalist design gaining share in full-face masks • Higher compliance vs. prior generation AirCurve 11TM ST Designed to support noninvasive ventilation AirCurve 11TM ST-A Expanded modes for patients whose ventilatory needs may change over time AirTouchTM F30i • Fabric-based full-face mask with two variants – Clear and Comfort DawnTM • Our digital sleep coach in myAirTM, had >1.5M inquiries since beta release • Allows patients to see their symptoms and interpret them in seconds • DawnTM is our best-in-class, active 24/7, in-house AI concierge leveraging 28B nights of sleep data across 35M cloud connected devices1 1 Data as of June 30, 2026. Additional data points in Appendix. v Devices Masks Digital
Page 11
Data Vis Active portfolio management: sharpening focus on growth areas 11© 2026 Resmed. Note: Data as of June 30, 2026. 1 Source: J Glob Health 2024;14:04113; Lancet Respiratory Medicine Aug 2025. 2 Includes MatrixCare, HEALTHCAREfirst, Citus, and select home health and hospice solutions. 3 Resmed provides no GAAP outlook for operating profit. A C Q U I S I T I O N Closed June 1, 2026 Noctrix Health FDA De Novo classified medical device for refractory moderate-to-severe Restless Legs Syndrome (RLS) P U R C H A S E P R I C E $340M All-cash F Y 2 7 R E V E N U E ~$30M F Y 2 7 E P S I M P A C T ~($0.20) Non-GAAP diluted S T R A T E G I C R A T I O N A L E ✓ RLS is the #3 most-prevalent sleep disorder, affecting ~17M adults in the U.S.1 ✓ Nidra is prescribed by sleep physicians and distributed by the same HME/DME channels as Resmed ✓ Scarce, fast-growing asset D I V E S T I T U R E Announced July 7, 2026 | Expected close ~September 1, 2026 MatrixCare Business2 S A L E P R I C E $490M All-cash F Y 2 6 R E V E N U E $220M $58M non-GAAP op. profit3 S T R A T E G I C R A T I O N A L E ✓ Sharpens focus on growth areas: sleep health, breathing health, and connected, home-based healthcare ✓ Accelerates growth & profitability of remaining RCS (Brightree + MEDIFOX DAN) ✓ In fiscal year 2027, RCS to deliver high single-digit revenue growth, with operating leverage U S E O F P R O C E E D S $450M Accelerated share repurchase I. Operational & Innovation Excellence II. Active Portfolio Management III. Business Investment & Return of Capital
Page 12
Data Vis + Increasing overall market growth via accelerating demand generation + Optimizing the patient pathway to diagnosis and therapy + Delivering on our pipeline of next-generation products + Continuing to drive operating excellence Underpinned by 2030 Strategy: 5-Year Global Outlook High single digits % Revenue Growth Earnings growth higher than revenue growth Accelerating shareholder returns; confident in our 5-year outlook 12© 2026 Resmed. ✓ Accelerating our share repurchase activity in FY27 ✓ Increased our quarterly dividend 10% to $0.66 per share Shareholder Returns I. Operational & Innovation Excellence II. Active Portfolio Management III. Business Investment & Return of Capital
Page 13
Financial Results and FY 2027 Guidance Q4
Page 14
Data Vis Q4 FY26 Global revenue results 14© 2026 Resmed. Residential Care Software Total Revenue $1.5 $5.7 Q4 FY26 FY26 Americas Sleep Devices Revenue RoW Sleep Devices Revenue Americas Masks & Other Revenue RoW Masks & Other Revenue Americas Life Support Devices Revenue RoW Life Support Devices Revenue $172 $676 Q4 FY26 FY26 $452 $1,731 Q4 FY26 FY26 $394 $1,513 Q4 FY26 FY26 $7 $37 Q4 FY26 FY26 $281 $1,073 Q4 FY26 FY26 $148 $572 Q4 FY26 FY26 $10 $51 Q4 FY26 FY26 +8% CC ⇧ (45%) ⇩ (38%) CC ⇩ +8% ⇧ +10% ⇧ +12% CC ⇧+13% CC ⇧+2% CC ⇧ Note: Data as of June 30, 2026. Resmed’s fiscal year end is June 30th. Note: See reconciliation to GAAP in Appendix. All $ in millions, unless noted otherwise. Note: All growth rates for the quarter are on a YoY HL basis and in CC where noted. Note: CC = constant currency. HL = headline. RoW = Rest of World. YoY = year-over-year. +8% CC ⇧ (36%) ⇩ (20%) CC ⇩ +8% ⇧ +13% ⇧ +9% CC ⇧+9% CC ⇧+4% CC ⇧ ($ in billions)
Page 15
Data Vis 62.3% 62.4% Q4 FY26 FY26 15 Q4 FY26 Rest of P&L © 2026 Resmed. Non-GAAP Operating Margin Non-GAAP Gross Margin1 Non-GAAP Earnings Per Share Free Cash Flow2 $2.95 $11.17 Q4 FY26 FY26 35.2% 36.1% Q4 FY26 FY26 $404 $1,650 Q4 FY26 FY26 90 bps ⇧ +16% ⇧ 10 bps ⇩ (21%) ⇩ ($ in actuals) ($ in millions) 240 bps ⇧ +17% ⇧ 180 bps ⇧ (1%) ⇩ Note: Data as of June 30, 2026. Resmed’s fiscal year end is June 30th. Note: See reconciliation to GAAP in Appendix. HL = headline. YoY = year-over-year. 1 $42M provision for expected costs associated with a field safety notice on Astral devices excluded. 2 $42M provision for expected costs associated with a field safety notice on Astral devices included.
Page 16
Data Vis 16 Executed against our strategic priorities in 2026 © 2026 Resmed. F L A G S H I P P R O D U C T AirSense 11 Global Rollout Continued progress across international markets I N N O V A T I O N F I R S T Resmed's First Fabric Masks New category of comfort-first mask design D I S C I P L I N E D M A R G I N E X E C U T I O N Gross Margin Expansion Continued productivity/pipeline execution and manufacturing/supply chain efficiencies I N T E G R A T I O N VirtuOx Integrated Home-based diagnostics now embedded in platform M & A : A C Q U I S I T I O N Noctrix Acquired Sleep health TAM expansion into RLS therapy M & A : D I V E S T I T U R E Announced MatrixCare Divestiture Sharpening focus on core growth areas Operational and Innovation Excellence Active Portfolio Management Invest in Business and Return Capital to Shareholders S H A R E H O L D E R R E T U R N $1B returned to shareholders1 Increase of 72% vs prior fiscal year D I V I D E N D P A Y O U T G R O W T H 12% Increase YoY $350M dividends paid I N V E S T I N G I N O U R B U S I N E S S $378M invested in R&D Invested 7% in R&D to fuel future innovation and growth Note: Data as of June 30, 2026. Resmed’s fiscal year end is June 30th. Note: See reconciliation to GAAP in Appendix. Note: YoY = year-over-year. 1 Includes share buybacks and dividends paid.
Page 17
Data Vis FY27 Revenue guidance: core constant currency and headline 17© 2026 Resmed. Note: Data as of June 30, 2026. Resmed’s fiscal year end is June 30th. Note: CC = constant currency. HL = headline. YoY = year-over-year. 5% - 7% YoY Core CC Revenue Growth Includes ~130 bps (or) ~$75M headwind from Astral For FY27 & FY26: • Only 2 months of MatrixCare revenue included • Noctrix revenue excluded $5.75B - $5.85B HL Total Revenue For FY27: • Only 2 months of MatrixCare revenue included • Noctrix revenue included • Assumes FX headwind of ~50 bps
Page 18
Data Vis FY27 Fully diluted non-GAAP EPS guidance 18© 2026 Resmed. $11.17 ($0.20) ($0.30) FY26 EPS (-) Noctrix (-) MatrixCare (+) Core contribution FY27 EPS $12.00 - $12.25112% - 14% Growth Note: Data as of June 30, 2026. Resmed’s fiscal year end is June 30th. Note: All forward looking non-GAAP fully diluted EPS figures are approximates. 1 Includes a total of ~$1.5 billion in share repurchases, including a $450 million ASR. $1.33 - $1.58
Page 19
Data Vis FY27 P&L guidance considerations 19© 2026 Resmed. Margin Expansion MaxtrixCare Business1 Update ✓ Expect low double-digit basis point non- GAAP gross margin expansion o Impacts from inflation across electronic components and freight, more than offset by continued productivity, efficiencies, and strategic pricing ✓ Guidance also assumes a slight increase in non-GAAP operating margin o Ongoing focus on re-investing in R&D and Marketing areas with high ROI, high impact $220M FY26 Revenue $58M FY26 Non-GAAP Operating Profit ✓ Ensure continuity across systems, processes, tools, and day-to-day operations ✓ Expected to largely offset stranded costs in year one post-close ✓ Remaining stranded costs to be mitigated and removed over time Entered into Transition Service Agreements (TSAs) Note: Data as of June 30, 2026. Resmed’s fiscal year end is June 30th. Note: Resmed provides non-GAAP outlook for operating profit. 1 Includes MatrixCare, HEALTHCAREfirst, Citus, and select home health and hospice solutions.
Page 20
Data Vis Strategic Growth Priorities Capital Returns to Shareholders FY27 capital expenditures of $160-180 million, supporting automation expansion and manufacturing footprint to address growing global demandCapEx Priorities Tuck-in size acquisitions: up to ~$500 million purchase pricePursue M&A FY27 quarterly dividend increased 10% to $0.66 per share, with a progressive dividend policySupport Dividends FY27 share repurchases ~$1.5 billion, including $450M ASRShare Repurchases Disciplined capital allocation strategy supports both business growth and return of capital to shareholders 20© 2026 Resmed. Note: Data as of June 30, 2026. Resmed’s fiscal year end is June 30th.
Page 21
Data Vis Q1 FY27 Preliminary trends 21© 2026 Resmed. Note: Data as of June 30, 2026. Resmed’s fiscal year end is June 30th. Note: QoQ = quarter-over-quarter. YoY = year-over-year. Core Constant Currency Revenue Down QoQ Q1 revenue typically down a few percentage points sequentially from Q4 Operating Expenses Roughly Flat QoQ Gross Margin Slightly Contracting YoY Gross margin to expand low double-digit basis points in FY27
Page 22
Data Vis Growth Transformation Shareholder Returns • Expanding the sleep opportunity • Optimizing the patient experience • Investing in the highest-ROI R&D and marketing initiatives • Disciplined capital allocation • Leveraging AI and technology • Finance transformation • Enhanced transparency • Commitment to dividend and opportunistic buybacks • Evaluating capital structure Chief Financial Officer key priorities 22© 2026 Resmed.
Page 23
Data Vis Large, underpenetrated, and growing target market Resmed remains a highly compelling investment opportunity 23© 2026 Resmed. Well-positioned to drive growth and serve more patients Differentiated financial profile delivering sustained shareholder value
Page 24
Contact Investor Relations Phone: +1 (858) 221-3304 Email: InvestorRelations@Resmed.com Website: Investor.Resmed.com
Page 25
APPENDIX
Page 26
Data Vis 400M RLS 480M COPD 1B+ People Sleep Apnea Underpenetrated OSA Market1 Sources (Lives in TAM): Sleep apnea – 936M, Benjafield et al Lancet Respir Med 2019 Insomnia – Sleep Medicine Reviews, Benjafield et al., August 2025 COPD – 480M, Boers et al JAMA Network Open 2023 Sleep Stats from Resmed 2026 sleep survey https://sleepsurvey.resmed.com/ 1. Resmed 2025 10-K 2. Resmed and Lancet Respiratory Medicine August 2025 M A R K ET F O R D EV I C ES M A R K ET F O R M A S K S Growing in the mid-single digits globally Growing in the high-single digits globally OSA patients diagnosed or treated <20% U.S. <10% Rest of World 2.7 B + People 850M Insomnia People who need health tech at home U.S. OSA Prevalence to Increase2 DRIVERS Aging | Higher average BMIs | 65% relative increase in prevalence in women GLP-1s impact limited (4%) ~77M adults by 2050 ~35% From 2020 Large, underpenetrated total addressable market = long runway for growth 26© 2026 Resmed. COMISA Overlap syndrome
Page 27
Data Vis Consumers are more focused on their health than ever before Wearables spotlight sleep apnea and sleep quality in general Consumers demand an elevated experience for healthcare products AI and digital health are changing how healthcare is delivered Massive pressure on healthcare systems; payers / providers are laser-focused on preventative care1 Widespread adoption of GLP-1 medications increases awareness of sleep apnea 1 Study published in SLEEP in 2026 involving 370k+ patients (including those with co-existing chronic diseases COPD, type 2 diabetes, depression, heart failure, and atrial fibrillation) and the medXcloud academic-industry collaborative, found (a) a consistent, dose-dependent reduction in hospitalizations and ER visits across all 5 comorbidity groups; (b) benefits emerging at just 2 to <4 hours of average nightly PAP use; (c ) each additional hour of PAP use linked to a 4.1-6.2% reduction in healthcare utilization over 12-24 months (p < 0.0001). Key megatrends are driving patients and providers to Resmed’s ecosystem 27© 2026 Resmed.
Page 28
Data Vis More than 28 billion nights of respiratory medical data (up ~2B) 37+ million patients in AirView 35+ million 100% cloud connectable devices worldwide 4.8+ million diagnostic tests processed in the cloud 182+ million accounts in Residential Care Software network v v 470+ API calls per second from integrators 12.5+ million patients have signed up for myAir vv 28 Up ~0.2M Up ~1M Up ~4M Up ~0.6M Up ~1M © 2026 Resmed. Note: Data as of June 30, 2026. Note: Data compares Q4 FY26 values vs. Q3 FY26 values. Note: All metrics are cumulative since their respective launch, with the exception of the API calls per second from integrators. Unmatched scale in connected respiratory & digital health ~Flat
Page 29
Data Vis DRAFT We envision a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home We create life-changing health technologies that people love We will create products people love as well as seamless, personalized pathways for access to life-changing care Empower our teams Prioritize AI Build trust We will achieve industry leading growth and profitability Our goal is to empower 500M people worldwide to achieve their full potential in 2030 Sleep Health Breathing Health Health Tech at Home OUR STRATEGY OUR FOCUS AREAS OUR MISSION OUR GLOBAL IMPACT OUR VISION OUR KEY CAPABILITIES OUR FINANCIAL GOAL Resolute integrity Resourceful innovation Responsible quality Respectful diversity Resounding impact OUR VALUES Drive collaboration Develop people Optimize for Resmed Lead others with purpose Own the results OUR BEHAVIORS © 2026 Resmed. 29 2030 Strategy
Page 30
Data Vis Reconciliation of non-GAAP financial measures The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles and field safety notification expenses and are reconciled below: (Unaudited; $ in thousands, except for per share amounts) Note regarding non-GAAP reconciliations 30© 2026 Resmed. (A) Resmed adjusts for the impact of the amortization of acquired intangibles, field safety notification expenses, restructuring expenses, gains on previously held equity investments, acquisition and portfolio review related expenses and associated effects, in addition to benefits from business cessation, and the effect of interest and penalties on refunds from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. Resmed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. Resmed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. Resmed believes this information provides investors better insight when evaluating Resmed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.
Page 31
Data Vis Reconciliation of non-GAAP financial measures (cont’d) The measures “non-GAAP selling, general, and administrative expenses” and “non-GAAP selling, general, and administrative expenses as a percentage of revenues” exclude acquisition and portfolio review related expenses and are reconciled below: Note regarding non-GAAP reconciliations (Unaudited; $ in thousands, except for per share amounts) 31© 2026 Resmed. (A) Resmed adjusts for the impact of the amortization of acquired intangibles, field safety notification expenses, restructuring expenses, gains on previously held equity investments, acquisition and portfolio review related expenses and associated effects, in addition to benefits from business cessation, and the effect of interest and penalties on refunds from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. Resmed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. Resmed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. Resmed believes this information provides investors better insight when evaluating Resmed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.
Page 32
Data Vis Reconciliation of non-GAAP financial measures (cont’d) The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below: Note regarding non-GAAP reconciliations (Unaudited; $ in thousands, except for per share amounts) 32© 2026 Resmed. (A) Resmed adjusts for the impact of the amortization of acquired intangibles, field safety notification expenses, restructuring expenses, gains on previously held equity investments, acquisition and portfolio review related expenses and associated effects, in addition to benefits from business cessation, and the effect of interest and penalties on refunds from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. Resmed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. Resmed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. Resmed believes this information provides investors better insight when evaluating Resmed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.
Page 33
Data Vis Note regarding non-GAAP reconciliations The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below: (Unaudited; $ in thousands, except for per share amounts) Reconciliation of non-GAAP financial measures (cont’d) 33© 2026 Resmed. (A) Resmed adjusts for the impact of the amortization of acquired intangibles, field safety notification expenses, restructuring expenses, gains on previously held equity investments, acquisition and portfolio review related expenses and associated effects, in addition to benefits from business cessation, and the effect of interest and penalties on refunds from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. Resmed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. Resmed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. Resmed believes this information provides investors better insight when evaluating Resmed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.